EOG Resources Inc vs Smith & Nephew plc — how do they compare? EOG Resources Inc trades at $148.51 (market cap $77.90B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: EOG Resources Inc is far larger — about 7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Smith & Nephew plc for 120 Days on average.
| EOG | SNN | |
|---|---|---|
Market Cap | $77.90B | $11.10B |
Volume | 2,930,386 | 1,051,703 |
Sector | Energy | Health |
52-Week High | $153.74 | $37.17 |
52-Week Low | $101.78 | $26.42 |
Typical Hold Time | 59 Days | 120 Days |
Enterprise Value | $81.24B | $14.13B |
Dividend Yield | 2.75% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $144.21, down 0.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $164.77 implying 14% upside. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations, while maintaining strong profitability with a 25.81% net income margin and 22.51% ROE. Recent news highlights operational strength and disciplined capital allocation, with upcoming Q3 2026 results scheduled for November 6, 2026.
EOG presents a compelling value opportunity with attractive valuation multiples (P/E of 11.22, EV/EBITDA of 5.68) and strong shareholder returns through dividends. Key risks include oil price volatility, as seen in recent sector pullbacks, and execution of growth targets amid macroeconomic uncertainty. The absence of sell ratings from analysts and institutional accumulation support a positive medium-term outlook, though investors should monitor energy market dynamics and quarterly results.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Trailing returns across standard periods
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →